Strategic Partners A/S

Strategic Partners A/S ROE

The Return on Equity (ROE) of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is -4.67 %. In the previous year, Return on Equity (ROE) was -1.55 % — a change of 201.70% (lower).

ROE

-4.67 %

YoY

201.70%

Last updated:

In 2025, Strategic Partners A/S's return on equity (ROE) was -4.67 %, a 201.70% increase from the -1.55 % ROE in the previous year.

The Strategic Partners A/S ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2018
-59.14 DKK
Jan 1, 2019
-637.16 DKK
Jan 1, 2020
-102.05 DKK
Jan 1, 2021
-6,708.84 DKK
Jan 1, 2022
-269.91 DKK
Jan 1, 2023
-182.90 DKK
Jan 1, 2024
-1.55 DKK
Jan 1, 2025
-4.67 DKK
The Strategic Partners A/S ROE history
YEARROEYoY
-4.67 %+201.70%
-1.55 %-99.15%
-182.90 %-32.24%
-269.91 %-95.98%
-6,708.84 %+6,474.07%
-102.05 %-83.98%
-637.16 %+977.42%
-59.14 %+188.51%
-20.50 %-93.81%
-330.89 %+414.17%
-64.35 %+76.48%
-36.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

ROE Details

Decoding Strategic Partners A/S's Return on Equity (ROE)

Strategic Partners A/S's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Strategic Partners A/S's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Strategic Partners A/S's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Strategic Partners A/S’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Strategic Partners A/S stock

Return on Equity (ROE) of Strategic Partners A/S is -4.67 % in 2025.

Return on Equity (ROE) of Strategic Partners A/S changed from -1.55 % to -4.67 %, representing a 201.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s Strategic Partners A/S with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Strategic Partners A/S

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Strategic Partners A/S